Endogenous phospholipase A2 inhibitors in snakes: a brief overview

• Published in: Journal of Venomous Animals and Toxins including Tropical Diseases
• Main Authors: Patrícia Cota Campos, Lutiana Amaral de Melo, Gabriel Latorre Fortes Dias, Consuelo Latorre Fortes-Dias
• Format: Article in Journal/Newspaper
• Language: English
• Published: SciELO 2017
• Subjects: PLA2 inhibitor; Phospholipase A2; Snake blood; Natural resistance; Snakes; Arctic medicine. Tropical medicine; RC955-962; Toxicology. Poisons; RA1190-1270; Zoology; QL1-991; Arctic
• Online Access: https://doi.org/10.1186/s40409-016-0092-5; https://doaj.org/article/fb49493112cd4e8bbdc1299cda32351d

Abstract The blood plasma of numerous snake species naturally comprises endogenous phospholipase A2 inhibitors, which primarily neutralize toxic phospholipases A2 that may eventually reach their circulation. This inhibitor type is generally known as snake blood phospholipase A2 inhibitors (sbPLIs). Most, if not all sbPLIs are oligomeric glycosylated proteins, although the carbohydrate moiety may not be essential for PLA2 inhibition in every case. The presently known sbPLIs belong to one of three structural classes – namely sbαPLI, sbβPLI or sbγPLI – depending on the presence of characteristic C-type lectin-like domains, leucine-rich repeats or three-finger motifs, respectively. Currently, the most numerous inhibitors described in the literature are sbαPLIs and sbγPLIs, whereas sbβPLIs are rare. When the target PLA2 is a Lys49 homolog or an Asp49 myotoxin, the sbPLI is denominated a myotoxin inhibitor protein (MIP). In this brief overview, the most relevant data on sbPLIs will be presented. Representative examples of sbαPLIs and sbγPLIs from two Old World – Gloydius brevicaudus and Malayopython reticulatus – and two New World – Bothrops alternatus and Crotalus durissus terrificus – snake species will be emphasized.